Ulocuplumab

DRUG3 trials

Sponsors

Bristol-Myers Squibb, Dana-Farber Cancer Institute

Conditions

Multiple MyelomaMultiple Myeloma in RelapseSolid TumorWaldenstrom's Macroglobulinemia

Phase 1

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

TerminatedNCT02472977

Bristol-Myers SquibbSolid Tumor

Start: 2015-07-13End: 2017-01-27Updated: 2018-11-01

A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia

TerminatedNCT03225716

Dana-Farber Cancer InstituteWaldenstrom's Macroglobulinemia

Start: 2017-10-20End: 2022-12-31Updated: 2024-05-03

Unknown Phase

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Dana-Farber Cancer InstituteMultiple Myeloma, Multiple Myeloma in Relapse

Updated: 2017-08-28

Related Papers

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia

Annals of Hematology2024-11-052 citations

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Blood2023-11-021 citations

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Blood2021-07-2150 citations

Genomic landscape of Waldenström's macroglobulinemia

HemaSphere2019-06-012 citations